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Abstract 
Background: Gonadotrophin-releasing hormone (GnRH) agonist is used for 
controlling ovarian stimulation in assisted reproductive technology (ART) cycles 
which has some benefits. 
Objective: To compare the efficacy of two different formulations of GnRH agonist: 
short-acting and long-acting, for ART protocols. 
Materials and Methods: In a prospective randomized study, one hundred women 
who underwent ART cycles were randomly divided into two groups. In group I, the 
patients received one single injection of 1.87 mg Triptorelin in previous mid-luteal 
phase. In group II, Decapeptyl 0.1 mg per day started from previous mid-luteal 
phase. Pregnancy outcome in in vitro fertilization (IVF) cycle was compared 
between two groups. 
Results: There were no statistically significant differences in the number of 
retrieved oocyte (p=0.545), fertilization (p=0.876), implantation (p=0.716) and 
pregnancy rate (p=0.727) between the two groups. 
Conclusion: There were not any advantages in IVF outcome between half-dose 
long-acting and short-acting GnRH agonist groups in ART cycle. 
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Introduction 
 
onadotrophin-releasing hormone 
agonist (GnRh) agonist is used for 
many women in order to control 
ovarian stimulation (COH) in assisted 
reproductive technology )ART( cycles. The 
benefits of GnRH agonist in COH include: 
preventing premature LH surge and 
luteinization, decreasing the cancellation rate 
of cycles, improving follicular recruitment, 
increasing the number of follicles, good quality 
oocyte and embryos. GnRH agonist is 
routinely used in long protocols (1-3). Two 
types of GnRH agonist are available which are 
used for desensitization of hypothesis in ART 
cycles: one type, short-acting GnRH agonist 
and another long-acting (depot form) (2, 4, 5).  
The pituitary desensitization time is no 
difference between long and short-acting 
GnRH-a, but the duration of short GnRH 
agonist action is shorter and it allows a 
quicker recovery of pituitary gonadotropin 
secretion after its withdrawal.  
Depot form of GnRH agonist has a longer 
half-life; however, there is concern about its 
unfavorable effects on embryo during early 
gestation (6-8). When short GnRH agonist is 
used for long protocol, it needs repeated daily 
administration for several days so this protocol 
is less acceptable by patients. Patient’s 
tolerance is better by single administration of 
depot from of GnRH agonist (5, 7, 9). 
The purpose of this study was to compare 
pregnancy outcome in two types of long 
GnRH agonist protocols: half-dose long-acting 
and short-acting GnRH agonist in ART cycles. 
 
Materials and methods 
 
The study was conducted in a prospective 
randomized manner from January 2010 to 
December 2011 at Yazd Research and 
G 
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Clinical Center for Infertility affiliated to Shahid 
Sadoughi University of Medical Sciences and 
was approved by the ethics committee of 
Yazd Research and Clinical Center for 
infertility.  
A signed informed consent was obtained 
from all of the patients who participated in the 
study. A total of 100 patients indicated for 
ART were included in this prospective 
randomized clinical trial as consort flow chart 
(figure 1). The patients were randomly divided 
into two groups by using packets which 
included Computerized randomization.  
The inclusion criteria was as follows: 
female age between 18-38 years, history of 
infertility at least for 1 year, and FSH 
concentration in day 3 of menstrual cycle <12 
mIU/ml. The patients with history of pelvic 
surgery, abnormal thyroid function or other 
endocrinopathies, and severe male factor 
(azoospermia) were excluded from the study.  
 
Ovarian stimulation protocol 
All patients underwent pituitary 
desensitization by the administration of GnRH 
agonist on day 21 of the preceding menstrual 
cycle. In long-acting GnRH agonist group 
(group I), half-dose (1.87 mg) of Triptorelin 
(Diphereline® S.R. 3.75mg, IPSEN, Pharma, 
France) was administrated in a single 
intramuscular injection in mid-luteal phase 
(day 21) of the previous menstrual cycle. In 
short acting group (group II), Decapeptyl 
(Decapeptyl® 0.1 mg, Ferring Co., Germany) 
was started 0.1 mg per day subcutaneously 
from previous mid-luteal phase and continued 
until the day of HCG injection.  
Ovarian stimulation was done from day 2 of 
menstrual cycle with daily administration (100-
150 IU) of human recombinant follicle-
stimulating hormone (Gonal-f, Serono Co., 
Aubnne, Switzerland) and continued until the 
day of HCG injection. Ovarian response was 
monitored using serial ultrasound 
examination. When the leading follicle was 
larger than 18mm in diameter or at least two 
follicles were larger than 16mm, 10000 IU 
HCG (pregnyl, ® organon, oss, Netherlands) 
was injected intramuscularly. Oocyte was 
retrieved 36 hours after HCG injection using a 
17-gauge aspiration needle under trans-
vaginal ultrasound guidance. Oocyte was pre 
incubated in the medium at 37oC with 6% CO2 
for 4-6 hours and inseminated by conventional 
IVF or intracytoplasmic sperm injection (ICSI). 
The fertilization was confirmed when two polar 
bodies and two pronuclear were observed 18-
20 hours after insemination and 1-3 embryos 
were transferred 2-3 days after oocyte 
retrieval.  
The luteal phase support was initiated from 
the day of oocyte retrieval with 100 mg 
Progesterone in oil (Progesterone, Abureihan 
Co., Tehran, Iran) per day. Serum βhCG was 
measured after 14 days of embryo transfer. 
The clinical pregnancy was confirmed by 
observation of the fetal heart activity through 
trans-vaginal ultrasonography 4-5 weeks after 
oocyte retrieval.  
 
Statistical analysis 
Statistical analysis was performed 
using the statistical package for the social 
science (SPSS software version 15.0 for 
windows, Chicago, IL). Both t-test and 
Chi-square test were used to detect 
significant differences (p<0.05) of the all 
variables between the two groups.  
 
Results 
 
A total of 100 patients were scheduled in 
this study (50 patients in each group). There 
were no differences in age, BMI, baseline 
FSH, etiology and duration of infertility 
between the two groups (Table I).  
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There were also no differences in the 
number of Gonal-F used ampoules, estradiol 
level, and endometrial thickness on the day of 
HCG injection, and duration of stimulation 
between the two groups (Table II). The 
number of retrieved oocyte, total number of 
embryos, fertilization rate, implantation rate, 
and clinical pregnancy rate were similar in 
both groups (Table III).  
 
 
 
 
 
Table I. Basic characteristics of patients in long-acting and short-acting Decapeptyl groups 
Basic characteristics 
Group I 
(Long-acting Decapeptyl) 
Group II 
(Short-acting Decapeptyl) 
p-value 
Age (Years) 
 
28.35 ± 6.7 28.30 ± 4.7 0.927 
BMI (Kg/m2) 
 
25.00 ± 3.2 24.30 ± 3.6 0.557 
Basal FSH (mIU/ml) 
 
6.90 ± 2.6 6.10 ± 2.5 0.132 
BMI: Body Mass Index. 
P-value<0.05 was significant. Student t test and Mann-Whitney test as appropriate. 
 
 
 
 
 
 
 
Table II. Etiology of infertility in long-acting and short-acting Decapeptyl groups 
Etiology 
Group I 
(Long-acting Decapeptyl) 
Group II 
(Short-acting Decapeptyl) 
p-value 
Tubal factor 
 
5% 7.5% 0.979 
Ovulatory factor 
 
35% 37.5% 1.000 
Endometriosis 
 
10% 5% 0.661 
Unexplained 
 
15% 10% 1.000 
Male factor 
 
35% 40% 0.910 
P-value<0.05 was significant. Chi-square test. 
 
 
 
 
 
 
 
Table III. ART outcome in long-acting and short-acting Decapeptyl groups 
ART outcome 
Group I 
(Long-acting Decapeptyl) 
Group II 
(Short-acting Decapeptyl) 
p-value 
No. of  retrieved oocyte 
 
8.35 ± 2.68 8.90 ± 3.00 0.545 
Total No. of embryos 
 
4.95 ± 1.66 5.25 ± 2.02 0.612 
Fertilization rate (%) (Per cycle) 
 
55.5  52.1  0.876 
No. of transferred embryos 
 
2.40 ± 2.5 2.45 ± 0.75 0.807 
Implantation rate (%) 
 
14 17 0.716 
Clinical pregnancy rate (%) (Per cycle) 
 
25 30 0.727 
P-value<0.05 was significant. Mann-Whitney test and Chi-square test. 
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Figure 1. Consort flow diagram. 
 
Discussion 
 
In the present study, we compared two 
hypothalamic down-regulation/COH protocols; 
the half dose of depot form of Triptorelin and 
short-acting form of Decapeptyl. No difference 
was observed regarding number of retrieved 
oocyte and embryo and fertilization, 
implantation and pregnancy rates in both 
groups. In spite of our study, a recently-
published analytical study has concluded that 
duration of stimulation and total number of 
FSH ampoules is significantly higher in depot 
form GnRH agonist group compared to short 
acting GnRH agonist group (10).  
Total doses of gonadotropin are so 
important that should be taken into careful 
consideration by both physicians and patients 
when choosing the type of protocol and it can 
change the cost of COH (10-13). Dal pratu et 
al compared half dose (1.87 mg) and full dose 
(3.75 mg) of depot Triptorelin. They found no 
significant difference in pregnancy and 
implantation rates between the two groups, 
but their results indicated that the number of 
administrated FSH ampoules were lower in 
half dose Triptorelin group (1). 
In a similar study Yim et al concluded that 
half-dose of GnRH agonist was as effective as 
full-dose of GnRH-a. Owing to lower dose of 
HMG ampoules used, they recommended 
half-dose of GnRH in order to reduce the cost 
of treatment (2). Although our results showed 
that pregnancy rates were similar in both 
groups. Yael Gonen et al proved the 
superiority of short-acting GnRH agonist over 
long-acting agonist in achievement of 
pregnancy outcome (14).  
In some other studies, long-acting and 
short-acting GnRH agonist were compared 
and showed similar ART outcome in two types 
of GnRH agonist. Therefore, depot form was 
recommended in ART cycles for patients’ 
convenience (4, 5, 7, 8, 15, 16) .Depot form of 
GnRH agonist has a longer half-life and 
blocks GnRH receptors for up to 4 weeks after 
a single injection (8). Thus, there is potential 
risk of embryo exposure in early pregnancy. 
Lahat et al reported a high incidence of 
attention deficit hyperactivity disorder in long 
term follow-up of children exposed to GnRH 
agonist in early pregnancy (17). However, 
Tarlatzis reported that the rate of abortion and 
the health of children born after ART were not 
Assessed for eligibility (n= 100) 
Excluded (n= 0) 
 Not meeting inclusion criteria (n= 0) 
 Declined to participate (n= 0) 
 Other reasons (n= 0) 
Analysed (n= 50) 
 Excluded from analysis (give reasons) (n= 0) 
Lost to follow-up (give reasons) (n= 0) 
 Discontinued intervention (give reasons) (n= 0) 
Allocated to intervention (n= 50) 
 Received allocated intervention (n= 50) 
 Did not receive allocated intervention (give 
reasons) (n= 0) 
Lost to follow-up (give reasons) (n= 0) 
 Discontinued intervention (give reasons) (n= 0) 
Allocated to intervention (n= 50) 
 Received allocated intervention (n= 50) 
 Did not receive allocated intervention (give 
reasons) (n= 0) 
Analysed (n= 50) 
Excluded from analysis (give reasons) (n= 0) 
Allocation 
Analysis 
Follow-Up 
Randomized (n= 100) 
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affected by the use of GnRH agonist protocol, 
altough some protocols were different success 
rate (18-20). Based on our findings, we 
recommend single dose depot form GnRH 
agonist for ART cycles, although its long-term 
effects on children require further 
investigation. 
 
Conclusion 
 
No advantage was found concerning 
implantation and pregnancy rate and number 
of retrieved oocyte between half-dose long-
acting and short-acting GnRH agonist groups 
in ART cycle. 
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